Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innate Pharma SA ( (FR:IPH) ) has issued an announcement.
On January 16, 2025, Innate Pharma reported its total number of shares and voting rights as of December 31, 2024, under the French ‘Code de Commerce’ and the AMF regulations. The company disclosed 83,830,336 ordinary shares, with additional preferred shares and a total of 84,585,576 theoretical voting rights. This announcement reflects Innate Pharma’s compliance with regulatory requirements, ensuring market transparency and informing stakeholders about its shareholding structure.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes its proprietary ANKET® platform for NK Cell Engagers, as well as Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs), to address various tumor types. Innate Pharma collaborates with biopharmaceutical companies such as Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. It is listed on Euronext Paris and Nasdaq.
YTD Price Performance: -40.0%
Average Trading Volume: 616
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $157.1M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.
